Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Medtronic (MDT) and Apellis Pharmaceuticals (APLS)

Tipranks - Tipranks - Thu Apr 2, 4:18AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Medtronic (MDT) and Apellis Pharmaceuticals (APLS).

End of Quarter Sale - 50% Off TipRanks

Medtronic (MDT)

Barclays analyst Matt Miksic maintained a Buy rating on Medtronic today and set a price target of $120.00. The company’s shares closed last Tuesday at $86.65.

According to TipRanks.com, Miksic is a 4-star analyst with an average return of 2.7% and a 51.5% success rate. Miksic covers the Healthcare sector, focusing on stocks such as Anteris Technologies Global Corp., GE Healthcare Technologies Inc, and Orchestra BioMed Holdings. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Medtronic with a $112.36 average price target, representing a 29.6% upside. In a report issued on March 20, TipRanks – PerPlexity also upgraded the stock to Buy with a $102.00 price target.

See today’s best-performing stocks on TipRanks >>

Apellis Pharmaceuticals (APLS)

In a report released today, Eliana Merle from Barclays maintained a Hold rating on Apellis Pharmaceuticals, with a price target of $41.00. The company’s shares closed last Tuesday at $40.23.

According to TipRanks.com, Merle is a 3-star analyst with an average return of 3.1% and a 39.7% success rate. Merle covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, Ultragenyx Pharmaceutical, and 4D Molecular Therapeutics. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Apellis Pharmaceuticals with a $33.69 average price target, implying a -16.6% downside from current levels. In a report released yesterday, Robert W. Baird also downgraded the stock to Hold with a $41.00 price target.

Read More on MDT:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).